Startups
Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our
Overview
Location
United States, Georgia, Norcross
Employees
11-50
Phone
+1 678-620-3186
Founded date
2000
Mentions in press and media 14
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 6, 2024 | Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist | |
| Jul 26, 2022 | Galectin gets $60M credit line from billionaire chair; Inflammatory disease biotech reaches SPAC deal | The chair of Galectin Therapeutics, billionaire and Jan. 6 pro-Trump rally financier Richard Uihlein, is offering up $60 million in an unsecured credit facility to the biotech. Almost 15 years ago, Uihlein began invest... |
| Dec 21, 2021 | Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein | NORCROSS, Ga., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has closed on the second $10 million convertible note pu... |
| Dec 21, 2021 | Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein | NORCROSS, Ga., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has closed on the second $10 million convertible note pu... |
| Dec 21, 2021 | Galectin Therapeutics : Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein - Form 8-K | Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein NORCROSS, Ga., December 21, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeut... |
| Sep 21, 2021 | Galectin Therapeutics : Announces $20 Million Convertible Debt Financing from Its Chairman, Richard E. Uihlein | NORCROSS, Ga., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has entered into a $20 million convertible debt financi... |
| Sep 21, 2021 | Galectin Therapeutics : Announces $20 Million Convertible Debt Financing from Its Chairman, Richard E. Uihlein (Form 8-K) | Galectin Therapeutics Announces $20 Million Convertible Debt Financing from Its Chairman, Richard E. Uihlein NORCROSS, Ga., September 21, 2021 (GLOBE NEWSWIRE) - Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutic... |
| Aug 16, 2021 | Galectin Therapeutics : Considering options for a Combination Cancer Immunotherapy trial based on encouraging results of Phase 1b trial which strengthened the rationale to conduct a larger, randomized controlled Phase 2 study (Form 8-K) | Considering options for a Combination Cancer Immunotherapy trial based on encouraging results of Phase 1b trial which strengthened the rationale to conduct a larger, randomized controlled Phase 2 study NORCROSS, Ga., August 16, 2021 (GLOBE ... |
| Apr 28, 2017 | Three major variables that could derail the dash to NASH | It’s a super-sized epidemic that many experts believe holds blockbuster therapeutic potential. That’s driven dozens of companies to enter the so-called “dash to NASH” in hot pursuit of the first FDA approval. As could be expected, there are... |
Show more
Reviews 0
FAQ about Galectin Therapeutics
When was Galectin Therapeutics founded?
Galectin Therapeutics was founded in 2000.
What has the press written about Galectin Therapeutics?
Parsers VC has collected 14 articles mentioning Galectin Therapeutics, among them “Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist” (Mar 6, 2024) and “Galectin gets $60M credit line from billionaire chair; Inflammatory disease biotech reaches SPAC deal” (Jul 26, 2022).
Is Galectin Therapeutics still active?
Yes, Galectin Therapeutics is active; its latest activity on Parsers VC dates from Mar 12, 2024.